Highlights the growing use of GLP-1 receptor agonists as an emerging treatment approach for women with Polycystic Ovary Syndrome (PCOS) in India. The article explores how medications like semaglutide and tirzepatide, originally approved for diabetes and obesity, are increasingly being prescribed off-label to address underlying metabolic issues such as insulin resistance, weight gain, and hormonal imbalance. According to Dr Shweta Wazir, there is a noticeable shift from symptom-based treatment to a metabolic-focused approach, with GLP-1 therapies showing improvements in menstrual regularity, skin concerns, and fertility outcomes. The coverage also highlights patient experiences, rising adoption trends, and the role of multi-specialty care involving endocrinologists, gynaecologists, and dermatologists. While early results appear promising, experts caution that further clinical research and regulatory clarity are needed, as these therapies are not yet officially approved for PCOS treatment.